Relationship between  the angiotensin Ⅱ type 2 receptor A1675G polymorphism and antihypertensive effect of  valartan

Abstract

Abstract: AIM: To study the relation of single nucleotide polymorphism of angiotensin Ⅱ receptor 2(AGTR2) A1675G with essential hypertension(EH) and antihypertensive response to valsartan.METHODS: Eighty case essential hypertension patients were received valsartan once daily for four weeks. Direct DNA sequencing was performed to detect the signgle nucleotide polymorphisms in eighty patients with essential hypertension and fourty normal blood pressure controls.RESULTS: There were significant differences of A1675G allele frequency between hypertensive group and normal controls(P<0.05).Treated with valsartan, patients with A allele had greater reduction in blood pressure (P<0.05).CONCLUSION: The results indicates that the AGTR2 A1675G single nucleotide polymorphisms might involved the development of essential hypertension and it is associated with antihypertensive predictor of valartan.

Key words: Hypertension, Angiotensin Ⅱ , Receptor, Single nucleotide polymorphisms, Valartan

CLC Number:

R544.1

LI Gang-qiang, YAN Wei, CHAO Sheng-wu, FAN Ji-hai. Relationship between the angiotensin Ⅱ type 2 receptor A1675G polymorphism and antihypertensive effect of valartan[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(2): 185-188.

References

[1] John H, Andrew S. Genome-wide association studies and human disease[J]. N Engl J Med, 2009,360(10):1759-1768.
[2] Severino G, Zompo M. Adverse Drug reactions: role of pharmacogenomics[J]. Pharmacol Res, 2004, 49(4):361-373.
[3] Romkes M, Buch SC. Genotyping technologies: Application to biotransformation enzyme genetic: polymorphism screening[J]. Methods Mol Bio, 2005, 291(7):399-414.
[4] 沈杰, 谢海棠, 刘昭前. 遗传药理学与高血压药物治疗进展[J]. 中国临床药理学与治疗学, 2010, 15(6): 705-714.
[5] Martin MM, Elton TS. The sequence and genomic organization of the human type 2 angiotensin Ⅱreceptor[J].Biochem Biophys Res Commun, 1995, 209(6):554-562.
[6] 宇大伟,乔卫卫,徐志颖,等. 血管紧张素Ⅱ2型受体基因多态性与男性高血压病及左心室肥厚的关系[J]. 山东医药, 2010, 50(33):55-56.
[7] Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism[J]. Hypertension, 1998, 31(12):349-355.
[8] Hunley TE, Tamura M, Stoneking BJ, et al. The angiotensin type Ⅱreceptor tonically inhibits angiotensin-converting enzyme in AT2 null mutant mice[J]. Kidney Int, 2000, 57(8):570-577.
[9] Siragy HM, Inagami T, Ichiki T,et al. Sustained hypersensitivity to angiotensin Ⅱ and its mechanism in mice lacking the subtype-2(AT2)angiotensin receptor[J]. Proc Natl Acad Sci U S A, 1999, 96(6):6506-6510.
[10] Vervoort VS, Beachem MA, Edwards PS, et al. AGTR2 mutations in X-linked mental retardation[J]. Science, 2002, 296(2):2401-2403.
[11] Schmieder RE, Erdmann J, Delles C, et al. Effect of the angiotensin Ⅱ type 2-receptor gene(+1675G/A) on left ventricular structure in humans[J]. J Am Coll Cardil, 2001,37(2):175-182.
[12] Jin JJ, Nakura J, Wu Z, et al. Association of angiotensin Ⅱtype 2 receptor gene variant with hypertension[J]. Hypertens Res, 2003,26(4):547-552.
[13] Carey RM, Wang ZQ, Siragy HM. Role of the angiotensin type2 receptor in the regulation of blood pressure and renal function[J].Hypertension, 2000, 35(1): 155-163.
[14] 曹东平, 彭应心, 姚文静,等. 缬沙坦-氢氯噻嗪合用治疗高血压早期肾损害的疗效[J]. 中国临床药理学与治疗学, 2009, 14(5):567-571.

[1]	ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin. Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
[2]	WANG Anjing, WANG Yaya, LIANG Xuan, YAN Yajie, SU Jing, LI Caidong. Research progress on mechanisms and therapeutic drugs of peroxisome proliferator-activated receptor in treatment of cholestatic liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 796-808.
[3]	ZHOU Jing, ZHOU Chen, LIAO Ke, QIU Ailin, DONG Weilei, GUO Zifen. Correlation between progesterone receptor G1978T polymorphism and endometrial cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 400-406.
[4]	LI Ruoning, GUO Zhanli, WANG Yuan, SUN Jianjun. Platelet-endothelial aggregation receptor 1 and its mediated signalling pathway Advances in the study of the role of platelets and endothelial cells [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 438-444.
[5]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[6]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[7]	ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074.
[8]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[9]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[10]	LI Hao, LI Ling, XIA Zhiping, YE Qifa, PENG Guizhu. FXR agonist GW4064 ameliorates tacrolimus-induced abnormalities in glucose metabolism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 466-472.
[11]	PENG Juan, FAN Linlin, LI Ranyi, LI Xiaoyu, LV Qianzhou, ZOU Yunzeng. Progress of pharmacotherapy for heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 373-381.
[12]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
[13]	CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
[14]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[15]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.

Relationship between the angiotensin Ⅱ type 2 receptor A1675G polymorphism and antihypertensive effect of valartan

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments